US Army selects Battelle to develop vaccines for biological and chemical threats

25 May 2016 (Last Updated May 25th, 2016 18:30)

The US Army Joint Program Executive Office for Chemical and Biological Defense has chosen Battelle to develop vaccines and therapeutics for biological and chemical threats.

The US Army Joint Program Executive Office for Chemical and Biological Defense has chosen Battelle to develop vaccines and therapeutics for biological and chemical threats.

A $59m contract to this effect has been awarded to the company.

The five-year contract was awarded as part of the General Service Administration's (GSA) OASIS contracting vehicle, which is open to federal government agencies worldwide.

"We're proud of the work we do at Battelle to protect people from threats like the Ebola and Zika viruses or ricin."

To date, Battelle has received awards in all seven unrestricted OASIS pools established by GSA.

Under the new contract, the company will develop vaccines for potentially weaponised viruses, such as plague, botulinum, equine encephalitis, and filovirus.

It will also develop medical countermeasures against nerve agents and poisonous toxins used in chemical warfare.

Battelle Life Sciences Research group general manager Julie Swick said "We're proud of the work we do at Battelle to protect people from threats like the Ebola and Zika viruses or ricin.

"Our dedicated employees come into work every day knowing they are contributing solutions to important, worldwide problems."

Battelle conducts research and development, as well as designs and manufactures products at major technology centres and national laboratories around the world.

In addition to national security interests, the company serves the health and life sciences, energy and environmental industries.